Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LFCR 
Lifecore Biomedical Inc. (LFCR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: LFCR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 14.04% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 281.31M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 3 | Beta 0.64 | 52 Weeks Range 4.33 - 8.85 | Updated Date 09/14/2025 |
52 Weeks Range 4.33 - 8.85 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.27 |
Earnings Date
Report Date 2025-08-25 | When After Market | Estimate -0.035 | Actual -0.06 |
Profitability
Profit Margin -30.04% | Operating Margin (TTM) 7.96% |
Management Effectiveness
Return on Assets (TTM) -3.04% | Return on Equity (TTM) -76.41% |
Valuation
Trailing PE - | Forward PE 8.67 | Enterprise Value 403865550 | Price to Sales(TTM) 2.18 |
Enterprise Value 403865550 | Price to Sales(TTM) 2.18 | ||
Enterprise Value to Revenue 3.13 | Enterprise Value to EBITDA 8.11 | Shares Outstanding 37407900 | Shares Floating 19047364 |
Shares Outstanding 37407900 | Shares Floating 19047364 | ||
Percent Insiders 1.99 | Percent Institutions 76.48 |
Upturn AI SWOT
Lifecore Biomedical Inc.
Company Overview
History and Background
Lifecore Biomedical Inc. is a global biotechnology company. Founded in 1982, it has evolved from a research-focused organization to a commercial manufacturer specializing in hyaluronan (HA)-based products and contract development and manufacturing organization (CDMO) services.
Core Business Areas
- Hyaluronan (HA): Lifecore develops, manufactures, and sells HA-based products for ophthalmic, orthopedic, and aesthetic applications. HA is a naturally occurring polymer used in various medical and cosmetic procedures.
- Contract Development and Manufacturing Organization (CDMO): Lifecore provides CDMO services to pharmaceutical and medical device companies, including formulation, fill-finish, and packaging services.
Leadership and Structure
Lifecore Biomedical's leadership team consists of experienced executives in the biotechnology and pharmaceutical industries. The company has a structured organizational framework with departments focused on research and development, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- Ophthalmic HA: Lifecore provides HA for ophthalmic viscosurgical devices (OVDs) used in cataract surgery and other eye procedures. The market share information is hard to obtain, as this is integrated into medical instruments. The primary competitors are companies that manufacture ophthalmic medical devices using HA.
- Orthopedic HA: Lifecore supplies HA for viscosupplementation injections used to treat osteoarthritis.The market share information is hard to obtain, as this is integrated into medical instruments. The primary competitors are companies that manufacture orthopedic medical devices using HA.
- Aesthetic HA: Lifecore offers HA for dermal fillers and other aesthetic applications. The market share information is hard to obtain, as this is integrated into medical instruments. The primary competitors are companies that manufacture aesthetic medical devices using HA.
Market Dynamics
Industry Overview
The biotechnology industry is driven by innovation in drug discovery, medical devices, and advanced therapies. The market for HA-based products is growing due to the increasing demand for minimally invasive medical and cosmetic procedures.
Positioning
Lifecore Biomedical is positioned as a key player in the HA market, with a focus on high-quality HA production and CDMO services. Its competitive advantage lies in its expertise in HA chemistry and manufacturing capabilities.
Total Addressable Market (TAM)
The TAM for HA-based products is estimated to be in the billions of dollars, encompassing ophthalmic, orthopedic, and aesthetic applications. Lifecore is well-positioned to capture a significant share of this market with its diverse product portfolio and CDMO services.
Upturn SWOT Analysis
Strengths
- Strong expertise in hyaluronan (HA) technology
- Established CDMO services offering
- Diverse product portfolio across multiple applications
- Reputation for high-quality manufacturing
Weaknesses
- Reliance on a limited number of key customers
- Exposure to regulatory risks and compliance requirements
- Competition from larger biotechnology and pharmaceutical companies
- The HA market share data is difficult to trace.
Opportunities
- Expanding CDMO services to new pharmaceutical and medical device companies
- Developing new HA-based products for emerging medical applications
- Entering new geographic markets with its products and services
- Capitalizing on the growing demand for minimally invasive procedures
Threats
- Increasing competition from other HA manufacturers and CDMOs
- Changes in regulatory requirements for medical devices and pharmaceuticals
- Economic downturns that could impact demand for elective medical procedures
- Intellectual property risks
Competitors and Market Share
Key Competitors
- Allergan (ABBV)
- Sanofi (SNY)
- Galderma (not publicly traded directly, owned by private equity)
- Abbott (ABT)
Competitive Landscape
Lifecore Biomedical faces competition from larger, more established companies in the HA market. Its advantages include its expertise in HA chemistry and manufacturing capabilities. Its disadvantages include its smaller size and limited financial resources compared to its competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends cannot be discussed due to a lack of current financial data.
Future Projections: Future projections are unavailable due to a lack of recent analyst estimates.
Recent Initiatives: Recent initiatives include expansions in CDMO capabilities and development of new HA-based products.
Summary
Lifecore Biomedical Inc. is a biotechnology company with a strong focus on hyaluronan-based products and CDMO services. Its strengths lie in its expertise in HA technology and manufacturing capabilities. However, it faces challenges from larger competitors and regulatory risks. Future growth depends on expanding its CDMO services, developing new HA-based products, and entering new geographic markets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lifecore Biomedical Inc. website
- Company press releases
- Industry reports
- Market analysis reports
Disclaimers:
This analysis is based on publicly available information and estimates and should not be considered financial advice. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lifecore Biomedical Inc.
Exchange NASDAQ | Headquaters Chaska, MN, United States | ||
IPO Launch date 1996-02-15 | President, CEO & Director Mr. Paul Josephs | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 406 | Website https://www.lifecore.com |
Full time employees 406 | Website https://www.lifecore.com | ||
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of hyaluronate acid (HA) in bulk form, as well as formulated and filled syringes, cartridges, and vials for injectable products used in treating a range of medical conditions and procedures. Its product development services include analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and production of materials for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.